Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

BACKGROUND: A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng-Cai, Li, Yu-Hua, Guan, Xu-Hua, Hou, Li-Hua, Wang, Wen-Juan, Li, Jing-Xin, Wu, Shi-Po, Wang, Bu-Sen, Wang, Zhao, Wang, Lei, Jia, Si-Yue, Jiang, Hu-Dachuan, Wang, Ling, Jiang, Tao, Hu, Yi, Gou, Jin-Bo, Xu, Sha-Bei, Xu, Jun-Jie, Wang, Xue-Wen, Wang, Wei, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255193/
https://www.ncbi.nlm.nih.gov/pubmed/32450106
http://dx.doi.org/10.1016/S0140-6736(20)31208-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255193/
https://www.ncbi.nlm.nih.gov/pubmed/32450106
http://dx.doi.org/10.1016/S0140-6736(20)31208-3

Ejemplares similares